During the last session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares were 0.77 million, with the beta value of the company hitting 0.44. The 52-week high for the BCLI share is $3.34, that puts it down -542.31 from that peak though still a striking 75.0% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $36.45M, and the average trade volume was 985.73K shares over the past three months.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Brainstorm Cell Therapeutics, Inc. (BCLI) registered a 0.79% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.79% in intraday trading to $0.52, hitting a weekly high. The stock’s 5-day price performance is 14.06%, and it has moved by 1.13% in 30 days. Based on these gigs, the overall price performance for the year is -80.74%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Statistics show that Brainstorm Cell Therapeutics, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Brainstorm Cell Therapeutics, Inc. (BCLI) shares have gone up 184.21% during the last six months, with a year-to-date growth rate more than the industry average at 45.10% against 14.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.57%.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
